menu
    • menu
    [{"orgOrder":0,"company":"Invetx","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Invetx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invetx \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"Invetx \/ Invetx"},{"orgOrder":0,"company":"Invetx","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Invetx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invetx \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"Invetx \/ Invetx"},{"orgOrder":0,"company":"Invetx","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Invetx","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invetx \/ Invetx","highestDevelopmentStatusID":"2","companyTruncated":"Invetx \/ Invetx"},{"orgOrder":0,"company":"Invetx","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Invetx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Invetx \/ Casdin Capital","highestDevelopmentStatusID":"2","companyTruncated":"Invetx \/ Casdin Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Invetx

    Menu

    Invetx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health

                            Details : Based on AbCellera's successful delivery on multiple discovery campaigns under the original agreement, the scope of the collaboration has been expanded to include multiple new targets over several years.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 19, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Casdin Capital

                            Deal Size : $25.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

                            Details : The Series A Financing positions the company for rapid scaling of its novel platform and advancing its portfolio of innovative antibody therapeutics for veterinary use.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 29, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Casdin Capital

                            Deal Size : $25.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Recipient : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for A...

                            Details : The proprietary platform combines industry-leading technologies from partners AbCellera, Twist Bioscience and WuXi Biologics to develop fully species-specific, optimized and half-life-extended monoclonal antibodies (mABs) for veterinary use.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 16, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Recipient : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Invetx

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : Twist Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats

                            Details : Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will use its Twist Antibody Optimization (TAO) platform to engineer and optimize multiple antibodies against important disease targets in animal health.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 16, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : Twist Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth